Company Overview and News

 
Equifax Reels Under Cyber-Attack Effects, Buyouts a Positive

15h zacks
Equifax Inc. (EFX - Free Report) shares have declined 15.7% over the past year against 34.9% increase recorded by the industry. Last year’s cyber-attack at Equifax, which resulted in theft of highly-sensitive personal data of approximately 143 million consumers, has heavily tarnished the brand image, reputation and credibility of the company.

 
Avis Budget Banks on Partnerships & Technology Enhancements

15h zacks
Avis Budget Group, Inc. (CAR - Free Report) has rallied a massive 91.9% over the past year, significantly outperforming the 7.6% increase of the industry it belongs to. The company’s focus on widening its global network and coverage, and enhancing technology to improve its offerings is commendable.

 
Intuit (INTU) Beats Q3 Earnings Estimates, Revises Outlook

2018-05-23 zacks
Intuit Inc. (INTU - Free Report) delivered impressive third-quarter fiscal 2018 results. The company reported non-GAAP income (excluding stock-based compensation, amortization and other one-time items) from continuing operations of $4.82 per share, surpassing the Zacks Consensus Estimate of $4.67. The figure also increased 24% on a year-over-year basis. Quarter in Detail This tax-preparation related software maker reported revenues of $2.

 
TransUnion to Buy iovation, Boost Fraud Identity Services

2018-05-23 zacks
TransUnion (TRU - Free Report) has inked a deal to acquire Portland, OR-based authentication and fraud prevention solutions provider, iovation, for an undisclosed amount.

 
Here's Why You Should Add Accenture to Your Portfolio Now

2018-05-22 zacks
A wise investment decision involves buying well-performing stocks at the right time while selling those that are at risk. A rise in share price and strong fundamentals signal a stock’s bullish run.

 
Here's Why Interpublic (IPG) Should be in Your Portfolio

2018-05-21 zacks
A prudent investment decision involves buying well-performing stocks at the right time while selling those that are at risk. A rise in share price and strong fundamentals signal a stock’s bullish run.

 
TransUnion (TRU) to Acquire HPS, Boost Healthcare Suite

2018-05-21 zacks
TransUnion’s (TRU - Free Report) subsidiary — TransUnion Healthcare — inked a deal to acquire Healthcare Payment Specialists (“HPS”). Based in Fort Worth, TX, Healthcare Payment Specialists assists healthcare service providers in boosting medical reimbursements. The deal is expected to be closed in the second quarter of 2018, subject to pending regulatory approvals.

 
Here's Why You Should Hold On to Paylocity (PCTY) Stock

2018-05-18 zacks
Paylocity Holding (PCTY - Free Report) has an impressive earnings surprise history, having surpassed the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average positive surprise of 220.1%. With expected long-term earnings per share growth rate of 22% and a market cap of $3.03 billion, it seems to be a stock that investors need to retain in their portfolio if they are looking to reap long-term gains.

 
Is First Trust Rising Dividend Achievers ETF (RDVY) a Hot ETF Right Now?

2018-05-18 zacks
Launched on 01/07/2014, the First Trust Rising Dividend Achievers ETF (RDVY - Free Report) is a smart beta exchange traded fund offering broad exposure to the Large Cap ETFs category of the U.S. equity market.

 
Why Should You Retain Navigant Consulting in Your Portfolio?

2018-05-17 zacks
A prudent investment decision involves buying stocks that have solid prospects and selling those that carry risks. At times, it is rational to hold certain stocks that have enough potential but are weighed down by tough market conditions.

 
Interpublic's Unit Buys Cappuccino, Boosts Digital Content

2018-05-17 zacks
The Interpublic Group of Companies, Inc.’s (IPG - Free Report) subsidiary - Weber Shandwick – completed the acquisition of Cappuccino on May 15. Based in Sao Paulo, Brazil, Cappuccino is a digital marketing and technology agency. The financial terms of the deal have been kept under wraps.

 
Bill Ackman calls for a breakup of United Technologies - MarketWatch

2018-05-17 marketwatch
Billionaire hedge-fund manager Bill Ackman on Thursday called for a breakup of United Technologies Corp. saying the individual businesses are more likely to trade at fair value as independent companies.

 
Why Should You Retain Omnicom (OMC) Stock in Your Portfolio?

2018-05-17 zacks
A prudent investment decision involves buying stocks that have solid prospects and selling those that carry risks. At times, it is rational to hold certain stocks that have enough potential but are weighed down by tough market conditions.

 
TRU or DNB: Which Stock is More Attractive Post Q1 Earnings?

2018-05-17 zacks
The first-quarter reporting cycle has seen strong earnings and revenue growth, which is expected to reach its highest level in seven years.

 
Northrop Grumman: Buy This Growing Military Company For Total Return

2018-05-16 seekingalpha
Northrop Grumman's total return over-performed the Dow average for my 52.0-month test period by 143.48% which is fantastic.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

17h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 053015103